Author:
Olatunji Gbolahan,Kokori Emmanuel,Moradeyo Abdulrahmon Akanmu,Lema Kaleb,Ayo Olanipekun Ridwan,Obasanjo Opabode Muntaqim,Mustapha Mubarak Jolayemi,Stanley Anthony Chidera,Aderinto Nicholas
Abstract
Abstract
Background
Familial hypercholesterolemia (FH) poses a substantial risk of cardiovascular diseases. The recent approval of evinacumab signifies a breakthrough in FH management. This review synthesizes evidence from diverse clinical trials, examining evinacumab’s efficacy, safety, and broader impact on hypercholesterolemia.
Body
As highlighted by multiple trials, Evinacumab demonstrates robust efficacy in reducing LDL-C levels, particularly in refractory cases. Its sustained impact, evidenced by enduring reductions in LDL-C levels throughout extended treatment periods, positions it as a potential long-term solution. While the safety profile appears favorable, instances of deaths underline the importance of holistic clinical management and ongoing surveillance. The clinical implications are profound, suggesting evinacumab’s potential inclusion in guidelines for managing severe lipid disorders.
Conclusion
Future research directions emphasize inclusivity, diversity, and real-world applications to establish sustained efficacy and safety across diverse populations. Integrating evinacumab into clinical guidelines requires evidence-based recommendations, necessitating collaboration between researchers, clinicians, and guideline developers.
Publisher
Springer Science and Business Media LLC